Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

被引：37
作者：
Bidus, Michael A.
Webb, Joel C.
Seidman, Jeffrey D.
Rose, G. Scott
Boice, Charles R.
Elkas, John C.
机构：
[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA
[2] Washington Hosp Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20010 USA
[3] Washington Hosp Ctr, Dept Pathol, Washington, DC 20010 USA
来源：
GYNECOLOGIC ONCOLOGY | 2006年 / 102卷 / 01期
关键词：
micropapillary; low malignant potential; borderline; well-differentiated; serous; ovarian cancer; bevacizumab; VEGF;
D O I：
10.1016/j.ygyno.2006.03.048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background. Bevacizumab has demonstrated activity against a variety of solid tumors, including ovarian carcinoma. However, there have not been reproducible prognostic features associated with its activity. Cases. One patient each with recurrent, refractory well-differentiated serous-endometrioid ovarian carcinoma, micropapillary serous carcinoma of the ovary, and primary peritoneal micropapillary serous carcinoma were treated with single agent bevacizumab (15 mg/m(2) intravenously every 3 weeks). All three have had dramatic sustained responses of 15, 15, and 22 months' duration. Conclusion. Bevacizumab may have significant activity against well-differentiated ovarian carcinoma and micropapillary serous carcinomas of the ovary or peritoneum. Since these tumors are generally indolent and not responsive to adjuvant therapy, further investigation is warranted. Published by Elsevier Inc.
引用
收藏
页码：5 / 7
页数：3
相关论文
共 16 条
[1]   Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome [J].
Bristow, RE ;
Gossett, DR ;
Shook, DR ;
Zahurak, ML ;
Tomacruz, RS ;
Armstrong, DK ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2002, 86 (02) :163-170
[2]   Vascular endothelial growth factor expression in serous ovarian carcinoma:: Relationship with high mitotic activity and high FIGO stage [J].
Brustmann, H ;
Naudé, S .
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) :47-52
[3]   Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential [J].
Crispens, MA ;
Bodurka, D ;
Deavers, M ;
Lu, K ;
Silva, EG ;
Gershenson, DM .
OBSTETRICS AND GYNECOLOGY, 2002, 99 (01) :3-10
[4]   Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function [J].
Escuin, D ;
Kline, ER ;
Giannakakou, P .
CANCER RESEARCH, 2005, 65 (19) :9021-9028
[5]   Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system [J].
Ishioka, S ;
Sagae, S ;
Terasawa, K ;
Sugimura, M ;
Nishioka, Y ;
Tsukada, K ;
Kudo, R .
GYNECOLOGIC ONCOLOGY, 2003, 89 (03) :447-452
[6]   Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential [J].
Meinhold-Heerlein, I ;
Bauerschlag, D ;
Hilpert, F ;
Dimitrov, P ;
Sapinoso, LM ;
Orlowska-Volk, M ;
Bauknecht, T ;
Park, TW ;
Jonat, W ;
Jacobsen, A ;
Sehouli, J ;
Luttges, J ;
Krajewski, M ;
Krajewski, S ;
Reed, JC ;
Arnold, N ;
Hampton, GM .
ONCOGENE, 2005, 24 (06) :1053-1065
[7]   Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer [J].
Monk, BJ ;
Choi, DC ;
Pugmire, G ;
Burger, RA .
GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :902-905
[8]  
PETTERSSON F, 1988, ANN REPORT RESULTS T, V20, P110
[9]   RETRACTED: VEGF-targeted therapy in metastatic renal cell carcinoma (Retracted article. See vol. 16, pg. 1481, 2011) [J].
Rini, BI .
ONCOLOGIST, 2005, 10 (03) :191-197
[10]   Prognostic value of histologic grading of ovarian carcinomas [J].
Sato, Y ;
Shimamoto, T ;
Amada, S ;
Asada, Y ;
Hayashi, T .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (01) :52-56
12